




Cardiovascular and metabolic determinants of quality of life in patients with cancer

Ruben Evertz^{1,2} , Katharina Gödde¹, Christine Diehl^{1,3}, Miroslava Valentova^{1,2}, Tania Garfias-Veitel^{1,2}, Friederike Braulke^{4,5}, Gerald G. Wulf⁴, Tobias R. Overbeck⁴, Annalen Bleckmann^{4,6,7}, Alexander O. König⁸, Pia Weinländer^{9,10,11}, Sophia Potthoff^{9,10,11}, Sara Hadzibegovic^{9,10}, Alessia Lena^{9,10,11}, Ulrich Keller^{12,13,14}, Ulf Landmesser^{9,10,15}, Andreas Schuster^{1,2} , Markus S. Anker^{9,10,16}, Gerd Hasenfuß^{1,2} and Stephan von Haehling^{1,2*} 

¹Department of Cardiology and Pneumology, University of Göttingen Medical Center (UMG), Göttingen, Germany; ²German Center for Cardiovascular Research (DZHK), partner site Göttingen, 37075, Göttingen, Germany; ³Department of Paediatrics, University of Göttingen Medical Center (UMG), Göttingen, Germany; ⁴Department of Haematology and Medical Oncology, University of Göttingen Medical Center (UMG), Göttingen, Germany; ⁵Comprehensive Cancer Center G-CCC, University of Göttingen Medical Center (UMG), Göttingen, Germany; ⁶Department of Medicine, Hematology, Oncology, and Pneumology, University Hospital Münster, Münster, Germany; ⁷West German Cancer Center, University Hospital Münster, Münster, Germany; ⁸Department of Gastroenterology, University of Göttingen Medical Center (UMG), Göttingen, Germany; ⁹Department of Cardiology, Charité – Universitätsmedizin Berlin, Campus Benjamin Franklin (CBF), Berlin, Germany; ¹⁰German Center for Cardiovascular Research (DZHK), partner site Berlin, Berlin, Germany; ¹¹Division of Cardiology and Metabolism, Department of Cardiology (CVK), Charité University Medicine Berlin, Berlin, Germany; ¹²Department of Hematology, Oncology and Cancer Immunology, Charité – Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany; ¹³Max-Delbrück-Center for Molecular Medicine, Berlin, Germany; ¹⁴German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany; ¹⁵Berlin Institute of Health (BIH), Berlin, Germany; and ¹⁶Berlin Institute of Health Center for Regenerative Therapies (BCRT), Berlin, Germany

Abstract

Aims Maintaining quality of life (QoL) in patients with cancer has gathered significant interest, but little is known about its major determinants. We sought to identify determinants of QoL in patients undergoing cancer treatment as well as in treatment-naïve patients about to commence such therapy.

Methods and results QoL was assessed in 283 patients with cancer using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 questionnaire. All patients underwent a battery of tests including physical examination, resting electrocardiogram, hand grip strength, and biochemistry assessment. Using multivariable logistic regression, we found that age [odds ratio (OR) 0.954, 95% confidence interval (CI) 0.916–0.994], resting heart rate (OR 1.036, 95% CI 1.004–1.068), hand grip strength (OR 0.932, 95% CI 0.878–0.990), and the presence of cachexia (OR 4.334, 95% CI 1.767–10.631) and dyspnoea (OR 3.725, 95% CI 1.540–9.010; all $P < 0.05$) remained independently predictive of reduced QoL.

Conclusions Therefore, it may be reasonable to address circumstances that are affecting muscle mass, body weight, and heart rate to maintaining QoL; however, prospective studies to test these endpoints are required.

Keywords Quality of life; Cancer

Received: 16 May 2022; Revised: 17 August 2022; Accepted: 15 September 2022

*Correspondence to: Stephan von Haehling, German Center for Cardiovascular Research (DZHK), partner site Göttingen, 37075 Göttingen, Germany.

Email: stephan.von.haehling@web.de

Introduction

Clinical trials in oncology are mostly driven by survival and remission rates that have helped to improve both aspects in several types of cancer. These endpoints, however, largely neglect treatment effects surrounding cancer therapy itself like developing and/or treatable co-morbidities or psychosocial aspects. Chemotherapy regimens, for example, have made

significant progress but are frequently associated with severe side effects that influence aspects of physical, emotional, and social life and therefore patients' quality of life (QoL). Although survival and remission rates are obviously important, patients usually wish to maintain their mobility, QoL, and independence throughout their treatment. These points are mounting in the palliative setting, where their achievement is becoming more difficult as the underlying disease

advances. Maintaining QoL is therefore an important target during all periods of care for patients with cancer. The World Health Organization (WHO) has defined QoL as ‘an individual’s perception of their position in life in the context of the culture and value systems in which they live and in relation to their goals, expectations, standards, and concerns’ (WHOQOL Group 1993). As such, health-related QoL (HRQoL) becomes more important and embraces various dimensions including, but not limited to, physical, psychological, and social aspects. In the following, we only use the term QoL.

QoL can be assessed using a vast array of different tools. Such tools are in most cases questionnaires that have been developed over the last decades and whose use depends on the underlying illness. In 1987, the European Organisation for Research and Treatment of Cancer (EORTC) developed a health-related questionnaire, aligned to the needs of cancer patients. The first version was refined continuously, and in 1993, the EORTC Quality of Life Questionnaire Core 30 (QLQ-C30) was finalized and validated.^{1,2} It has been used in more than 2200 studies; however, the factors influencing QoL in cancer patients remain incompletely understood. The present study has been designed to establish a cardiovascular perspective of QoL in patients undergoing cancer treatment as well as in patients who are about to commence such therapy.

Materials and methods

Study population

Between September 2017 and March 2020, we prospectively enrolled 283 participants at the University of Göttingen Medical Centre and at Charité Medical School, Campus Benjamin Franklin, Berlin, both in Germany. Patients were identified by studying their medical records and eligible to participate in case of histologically confirmed malignant disease and an age of at least 18 years. There was no restriction in participation regarding patients’ treatment status. The following criteria were defined as reasons for exclusion: (i) clinical signs of an acute infection, antibiotic treatment due to an infection, or fever defined as a temperature $> 38.0^{\circ}\text{C}$; (ii) severe cardiovascular disease, defined as coronary heart disease, prior myocardial infarction, chronic or acute heart failure, and severe valvular heart disease; (iii) severe chronic obstructive pulmonary disease (COPD), defined as Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage $> \text{II}$ (except in lung cancer patients, all COPD GOLD stages were allowed); and (iv) any other cancer diagnosis in the 5 years preceding enrolment.

All participants underwent a standardized clinical evaluation, which included the acquisition of the patient’s medical history, a physical examination, a resting electrocardiogram

(ECG), blood collection, hand grip strength (HGS), and a QoL questionnaire (EORTC QLQ-C30).

The local ethics committees approved the study protocol, and written informed consent was obtained from all participants. The study was conducted according to the principles of the Declaration of Helsinki.

Blood collection

Patients underwent routine laboratory assessments including a full blood count, biochemistry, and kidney and liver function tests. In addition, serum and plasma samples were collected and immediately frozen at -80°C for later analysis. Full blood count and clinical chemistry parameters were analysed immediately by the local laboratory. High-sensitivity cardiac Troponin T (hs-Troponin T) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) were assessed using assays purchased from Roche Diagnostics (Roche Deutschland Holding GmbH, Grenzach-Wyhlen, Germany).

Cardiovascular assessment

Following the recording of the medical history, a detailed physical examination including measurement of body weight and height was performed. Blood pressure of all patients was assessed according to current guidelines issued by the European Society of Cardiology (ESC) in a sitting position in a quiet environment after a rest of at least 5 min.³ Three measurements were performed 2 min apart and results recorded as an average of the last two blood pressure readings. Measurements were performed using a bosco medicus electronic sphygmomanometer (Bosch + Sohn GmbH und Co KG, Juningen, Germany). Twelve-lead ECGs were recorded in a supine position after a rest of at least 5 min using a MAC™ 3500 Resting ECG System (GE Healthcare, Chicago, IL, USA).

Physical strength was evaluated by measuring HGS, which was performed in a sitting position with the elbow flexed at 90° , whereas shoulder and wrist were in neutral position (0°) using a Jamar® Plus + Digital Hand Dynamometer (Performance Health Holding, Inc., Warrenville, IL, USA). HGS was evaluated in both hands, and the average of three tests of the stronger hand noted. Cachexia was defined as a weight loss of at least 5% within the last 12 months or a combination of 2% weight loss and a body mass index (BMI) $< 20 \text{ kg/m}^2$. In patients presenting with dyspnoea, its extent was described in analogy to the New York Heart Association (NYHA) classification) used in patients with heart failure.

Quality of life

QoL was assessed once at the time of patients’ inclusion using the EORTC QLQ-C30 questionnaire, Version 3.¹ The

questionnaire contains functional scales (physical, role, cognitive, emotional, and social) and symptom scales (fatigue, pain, nausea and vomiting, dyspnoea, loss of appetite, insomnia, constipation, diarrhoea, and financial impact due to disease or treatment). In addition, the global health condition and patients' global QoL are gathered. Values between 0 and 100 can be reached. For the functional scales, higher values indicate a high level of functioning, whereas for the symptom scales, higher values indicate a higher symptom burden. The analysis of the gathered QoL data was done using a dedicated scoring manual.⁴ Acquired data were compared with thresholds deemed to have clinical importance, based on a publication by Giesinger *et al.*⁵ For further analysis, the study population was divided into two groups according to the median EORTC QLQ-C30 summary score, where a higher score indicates higher QoL.

Statistical analysis

Normally distributed data are expressed as mean \pm standard deviation, whereas non-normally distributed data are expressed as median with interquartile range. Normal distribution was tested using the Shapiro–Wilk test. Data not following normal distribution were compared using the Mann–

Whitney *U* and Kruskal–Wallis tests, as appropriate. For between-group comparisons in normally distributed data, Student's *t*-test and analysis of variance (ANOVA) testing were performed, as appropriate. For binary variables, intergroup comparisons were performed using the χ^2 test.

Univariable and multivariable logistic regression models were used to identify clinical determinants of QoL in patients with cancer. A *P*-value < 0.05 was considered statistically significant. Statistical analysis was performed using IBM SPSS Statistics Version 26 for Windows [International Business Machines Corporation (IBM® Corp.), Armonk, NY 10504, USA].

Results

Study population characteristics

Patients' baseline characteristics are summarized in *Table 1*. The EORTC QLQ-C30 questionnaire was completed by all 283 patients. A total of 52.4% of the cohort were male; the mean age was 61.2 ± 13.0 years with age ranging from 20 to 87 years. A total of 60.8% of patients were suffering from a solid tumour, whereas the remaining 39.2% had malignant haematological diseases (*Figure 1*). Most cancer types in the


Table 1 Baseline characteristics of the study population divided by EORTC QLQ-C30 summary score median

	Study population (<i>n</i> = 283)	EORTC QLQ-C30 summary score < median (<i>n</i> = 141)	EORTC QLQ-C30 summary score \geq median (<i>n</i> = 142)	<i>P</i> -values
Demographic data				
Age (years)	61.2 \pm 13.0	60.7 \pm 13.6	61.6 \pm 12.5	0.576
Sex (male)	148 (52.3%)	63 (44.6%)	85 (59.9%)	0.012
Height (cm)	172 \pm 9	171 \pm 9	174 \pm 9	0.007
Weight (kg)	75.7 \pm 17.6	72.7 \pm 17.3	78.6 \pm 17.5	0.004
Body mass index (kg/m ²)	25.4 \pm 4.8	24.84 \pm 5.08	25.94 \pm 4.53	0.055
Haematology and oncology data				
Solid tumour	172 (60.8%)	81 (57.4%)	91 (64.1%)	0.274
UICC stage	I = 3 (1.7%) II = 8 (4.7%) III = 14 (8.1%) IV = 147 (85.5%)	I = 1 (1.3%) II = 3 (3.8%) III = 6 (7.5%) IV = 70 (86.5%)	I = 2 (2.2%) II = 5 (5.4%) III = 8 (8.7%) IV = 77 (83.7%)	0.892
Haematological neoplasia	111 (39.2%)	60 (42.6%)	51 (35.9%)	0.274
Ann-Arbor stage	I = 23 (22.8%) II = 15 (14.9%) III = 25 (24.8%) IV = 38 (37.6%)	I = 7 (11.2%) II = 10 (16.6%) III = 16 (26.7%) IV = 23 (38.3%)	I = 16 (31.3%) II = 5 (9.8%) III = 9 (17.6%) IV = 15 (29.4%)	0.052
Deceased	110 (38.9%)	55 (39.0%)	55 (38.7%)	0.962
Treatment naïve	53 (18.7%)	23 (16.3%)	30 (21.1%)	0.361
Co-morbidities				
Cachexia	131 (46.3%)	79 (56.0%)	52 (36.6%)	0.001
Hypertension	120 (42.4%)	59 (41.8%)	61 (43.0%)	0.904
Anaemia	181 (64.0%)	101 (71.6%)	80 (56.3%)	0.009
Diabetes mellitus	26 (9.2%)	12 (8.5%)	14 (9.9%)	0.837
Current smoker	68 (24%)	43 (30.7%)	25 (17.6%)	0.012
Dyspnoea (NYHA class \geq II)	49 (17.3%)	31 (22.0%)	18 (12.7%)	0.003

EORTC, European Organisation for Research and Treatment of Cancer; NYHA, New York Heart Association; QLQ-C30, Quality of Life Questionnaire Core 30; UICC, Union for International Cancer Control.

Data are expressed as mean \pm standard deviation or number (percentage).

The bold values indicate significant *P*-values (defined as $P \leq 0.05$).

Figure 1 Tumour type distribution in the studied population. ENT, ear–nose–throat.**Table 2** Baseline characteristics of the study population divided by EORTC QLQ-C30 summary score median

	Study population (n = 283)	EORTC QLQ-C30 summary score < median (n = 141)	EORTC QLQ-C30 summary score ≥ median (n = 142)	P-values
Blood count				
Haemoglobin (g/dL)	11.7 ± 2.1	11.2 ± 2.1	12.2 ± 2.0	<0.001
Haematocrit (%)	34.7 ± 5.9	33.3 ± 5.9	36.1 ± 5.6	<0.001
Erythrocytes (x 10 ⁶ /μL)	3.90 ± 0.72	3.76 ± 0.74	4.05 ± 0.67	0.001
Platelets (x 10 ³ /μL)	238 (173–312)	242 (166–315)	236 (185–305)	0.999
Leucocytes (x 10 ³ /μL)	6.13 (4.63–8.51)	6.08 (4.49–8.29)	6.17 (4.64–8.58)	0.556
Clinical chemistry panel				
Sodium (mmol/L)	140 ± 3.4	139.11 ± 3.60	139.99 ± 3.22	0.031
Potassium (mmol/L)	4.0 ± 0.5	3.9 ± 0.5	4.0 ± 0.4	0.003
Iron (μmol/L)	12.2 (8.2–18.5)	11.4 (7.8–16.5)	13.4 (8.7–19.5)	0.125
Transferrin (g/L)	2.14 (1.82–2.52)	2.06 (1.66–2.45)	2.19 (1.97–2.55)	0.007
Transferrin saturation (%)	22 (15–35)	22.00 (14–35)	22.00 (16–35)	0.707
Ferritin (μg/L)	326 (99–432)	291.8 (108–523)	191.9 (88–376)	0.020
Creatinine (mg/dL)	0.84 ± 0.25	0.84 ± 0.28	0.84 ± 0.22	0.944
Albumin (g/L)	37 ± 5	36 ± 5	38 ± 5	0.001
CRP (mg/L)	6.7 (2–18.7)	9.2 (2.4–23.7)	5.5 (1.7–11.6)	0.011
Cardiac biomarkers				
Troponin T (ng/L)	8 (5–14)	10 (5–18)	8 (4–12)	0.008
NT-proBNP (ng/L)	189 (84–465)	231 (102–548)	155 (75–321)	0.002

CRP, C-reactive protein; EORTC, European Organisation for Research and Treatment of Cancer; NT-proBNP, N-terminal pro-B-type natriuretic peptide; QLQ-C30, Quality of Life Questionnaire Core 30.

Data are expressed as mean ± standard deviation. Non-normally distributed data are expressed as median (25% and 75% percentile).

The bold values indicate significant P-values (defined as $P \leq 0.05$).

study population were classified as advanced disease [Union for International Cancer Control (UICC) stage ≥ III 93.6%; Ann-Arbor stage ≥ III 62.4%]. Mean BMI was 25.4 ± 4.8 kg/m² (range 15.4–41.6 kg/m²). The most common co-morbidities were anaemia (64.0%) followed by cachexia

(46.3%), hypertension (42.4%), and diabetes mellitus (9.2%). Dyspnoea, equivalent to NYHA class II or higher, was reported by 17.3% of all patients. The follow-up was censored in October 2020. Until this point, a total of 110 (38.9%) patients had died.

Quality of life

Patients were divided according to the median EORTC QLQ-C30 summary score with higher values indicating higher QoL. There were no significant differences with regard to age

($P = 0.58$), tumour type ($P = 0.27$), survival rate ($P = 0.96$), and therapy-naïve status ($P = 0.36$) between these two groups. Whereas cachexia ($P = 0.001$), anaemia ($P = 0.009$), status as current smoker ($P = 0.012$), and dyspnoea ($P = 0.003$) were more frequent in patients with lower QoL, no such difference

Table 3 Baseline characteristics of the study population divided by EORTC QLQ-C30 summary score median

	Study population ($n = 283$)	EORTC QLQ-C30 summary score < median ($n = 141$)	EORTC QLQ-C30 summary score \geq median ($n = 142$)	<i>P</i> -values
Physical diagnostic				
Heart rate (b.p.m.)	75 \pm 14	78 \pm 15	72 \pm 12	<0.001
BP systolic (mmHg)	129 \pm 20	129 \pm 21	129 \pm 19	0.506
BP diastolic (mmHg)	79 \pm 23	80 \pm 12	78 \pm 11	0.266
HGS (kg)	28.91 (22.49–37.25)	26.25 (20.61–34.73)	32.23 (24.16–39.86)	<0.001

BP, blood pressure; EORTC, European Organisation for Research and Treatment of Cancer; HGS, hand grip strength; QLQ-C30, Quality of Life Questionnaire Core 30.

Data are expressed as mean \pm standard deviation. Non-normally distributed data are expressed as median (25% and 75% percentile). The bold values indicate significant *P*-values (defined as $P \leq 0.05$).

Table 4 Quality of life characterization of the study population using EORTC QLQ-C30

	Study population ($n = 283$)	TCI	EORTC QLQ-C30 summary score < median ($n = 141$)	EORTC QLQ-C30 summary score \geq median ($n = 142$)	<i>P</i> -values
Global health status/ QoL scale (QL)	49.53 \pm 22.52 50 (33.33–66.67)		35.34 \pm 17.56 33.3 (25–50)	63.32 \pm 17.52 66.67 (50–75)	<0.001
Functional scales					
Physical (PF)	66.20 \pm 27.48 73.33 (46.67–86.67)	83	51.64 \pm 27.16 53.33 (33.33–73.33)	80.66 \pm 18.86 86.67 (71.67–93.33)	<0.001
Role (RF)	52.59 \pm 35.94 50 (16.67–83.33)	58	30.50 \pm 30.27 33.33 (0–50)	74.53 \pm 26.46 83.33 (66.67–100)	<0.001
Cognitive (CF)	76.80 \pm 25.76 83.33 (66.67–100)	75	62.65 \pm 27.23 66.67 (50–83.33)	90.84 \pm 13.83 100 (66.67–100)	<0.001
Emotional (EF)	63.19 \pm 28.18 66.67 (41.67–83.33)	71	44.86 \pm 23.39 41.67 (25–66.67)	81.40 \pm 19.36 83.33 (66.67–100)	<0.001
Social (SF)	55.89 \pm 33.75 66.67 (33.33–83.33)	58	36.17 \pm 30.01 33.33 (16.67–50)	75.47 \pm 24.68 83.33 (66.67–100)	<0.001
Symptom scales					<0.001
Fatigue (FA)	48.00 \pm 28.65 44.44 (33.33–67.67)	39	69.47 \pm 20.42 66.67 (55.56–88.89)	28.53 \pm 18.89 33.33 (11.11–44.44)	<0.001
Nausea and vomiting (NV)	11.90 \pm 19.75 0 (0–100)	8	19.42 \pm 24.29 16.67 (0–33.33)	4.49 \pm 9.32 0 (0–0)	<0.001
Pain (PA)	32.39 \pm 33.44 33.33 (0–50)	25	49.64 \pm 33.55 50 (16.67–83.33)	14.89 \pm 22.16 0 (0–33.33)	<0.001
Dyspnoea (DY)	32.51 \pm 34.66 33.33 (0–66.67)	17	49.40 \pm 37.07 33.33 (0–66.67)	15.60 \pm 21.66 0 (0–33.33)	<0.001
Insomnia (SL)	37.22 \pm 34.79 33.33 (0–66.67)	50	53.72 \pm 35.33 66.67 (33.33–66.67)	20.57 \pm 25.40 0 (0–33.33)	<0.001
Loss of appetite (AP)	32.39 \pm 39.91 33.33 (0–66.67)	50	52.04 \pm 38.09 66.67 (0–100)	12.29 \pm 21.24 0 (0–33.33)	<0.001
Constipation (CO)	16.37 \pm 29.76 0 (0–33.33)	50	25.18 \pm 35.86 0 (0–33.33)	6.86 \pm 17.14 0 (0–0)	<0.001
Diarrhoea (DI)	15.78 \pm 28.73 0 (0–33.33)	17	23.50 \pm 33.92 0 (0–33.33)	8.27 \pm 19.98 0 (0–0)	<0.001
Financial impact (FI)	22.22 \pm 30.72 0 (0–33.33)	17	28.54 \pm 34.18 0 (0–66.67)	15.60 \pm 24.74 0 (0–33.33)	0.001
QLQ summary score	68.25 \pm 19.55 71.15 (54.96–83.25)		52.42 \pm 14.18 54.96 (40.83–64.19)	83.96 \pm 8.09 83.08 (77.38–90.96)	<0.001

EORTC, European Organisation for Research and Treatment of Cancer; QLQ-C30, Quality of Life Questionnaire Core 30; QoL, quality of life; TCI, threshold for clinical importance.

Data are expressed as mean \pm standard deviation. Non-normally distributed data are expressed additionally as median (25% and 75% percentile).

The bold values indicate significant *P*-values (defined as $P \leq 0.05$).

was observed for hypertension ($P = 0.90$) and diabetes ($P = 0.84$). A trend towards lower BMI was recorded for patients with lower QoL ($P = 0.055$; *Table 1*). Laboratory findings for the two groups are given in *Table 2*. Haemoglobin, haematocrit, erythrocyte count, transferrin, sodium, and potassium values were significantly reduced in patients with lower QoL (all $P < 0.05$). In contrast, ferritin, C-reactive protein (CRP), and cardiac biomarkers were significantly lower in patients with a QoL summary score above or equal the median (all $P < 0.05$) (*Table 2*). Whereas there were no significant differences in blood pressure, the heart rate was lower and the HGS higher in patients with a QoL summary score above or equal to the median than in the comparison group (both $P < 0.001$) (*Table 3*).

Determinants of quality of life

Results of the EORTC QLQ-C30 in the study population divided by the QLQ-C30 summary score are given in *Table 4*. Patients with a summary score above or equal to the median had consistently better functional status and overall lower symptom burden (all $P < 0.05$). *Figure 2* illustrates functional and symptom scales in direct comparison between the two groups. Comparing these data with thresholds of clinical im-

portance published by Giesinger *et al.*, the studied population showed clinically important variations in physical, role, emotional, and social functions (*Table 4*). From a symptomatic point of view, patients were primarily affected by fatigue, pain, nausea, and vomiting, as well as dyspnoea and loss of appetite. Finally, the study population was burdened by the financial impact of their individual disease.

Using univariable logistic regression, we found that female sex, lower body weight, lower height, the presence of cachexia, night sweats, current smoking, NYHA class \geq II, and the presence of anaemia were all associated with lower QoL (all $P < 0.005$). The same was true for different laboratory parameters like sodium, potassium, albumin, haemoglobin, and haematocrit in which decreasing values were associated with lower QoL. Increasing values in hs-Troponin T and NT-proBNP were also associated with lower QoL (*Table 5*). In addition, univariable logistic regression showed heart rate, heart rate \geq 75 b.p.m., and HGS to be significantly associated with lower QoL.

Adjusting for clinically relevant parameters, multivariable logistic regression showed age, heart rate, HGS, and the presence of cachexia and dyspnoea to be independent predictors of a lower QoL (*Table 5*). No material change was noted when variables were entered into the model with EORTC QLQ-C30 summary score entered as continuous dependent variable.

Figure 2 Comparative quality of life scores in tumour patients. The two groups are built by using the median summary score. Left: Values are reflecting functional scales. Higher values result in better 'performance'. Right: Values are reflecting symptom scales. Higher values mean higher symptom burden. All components demonstrated statistically significant differences ($P < 0.05$). EORTC, European Organisation for Research and Treatment of Cancer.




Table 5 Univariable and multivariable analyses for prediction of low QoL

Variable	Odds ratio (95% CI)	P-values
Univariable models		
Age (1 year increase)	0.995 (0.977–1.013)	0.575
Sex (male)	0.542 (0.338–0.868)	0.011
Currently alive (present)	0.989 (0.613–1.594)	0.962
Solid tumour (present)	0.757 (0.469–1.221)	0.253
Treatment naïve (present)	0.728 (0.399–1.328)	0.728
Height (1 cm increase)	0.966 (0.941–0.991)	0.008
Weight (1 kg increase)	0.980 (0.967–0.994)	0.005
BMI (1 kg/m ² increase)	0.953 (0.907–1.001)	0.057
Night sweat (present)	2.614 (1.457–4.689)	0.001
Cachexia (present)	2.266 (1.401–3.665)	0.001
Hypertension (present)	0.955 (0.596–1.531)	0.850
Anaemia (present)	1.957 (1.194–3.207)	0.008
Diabetes mellitus (present)	0.850 (0.379–1.910)	0.695
Current smoker (present)	2.075 (1.183–3.638)	0.011
Dyspnoea (present)	3.062 (1.505–6.227)	0.002
(NYHA class ≥ II)		
Sodium (1 mmol/L increase)	0.926 (0.862–0.994)	0.034
Potassium (1 mmol/L increase)	0.451 (0.262–0.774)	0.004
Haemoglobin (1 g/dL increase)	0.786 (0.697–0.886)	< 0.001
Haematocrit (1 unit increase)	0.919 (0.880–0.959)	< 0.001
Erythrocytes	0.556 (0.394–0.784)	0.001
Platelets	1.000 (0.998–1.002)	0.816
Leucocytes	0.990 (0.953–1.028)	0.608
Ferritin (10 µg/L increase)	1.004 (0.999–1.008)	0.096
TSAT (1 unit increase)	1.003 (0.992–1.015)	0.589
Albumin (1 g/L increase)	0.922 (0.878–0.969)	0.001
Log Troponin T (1 SD increase)	2.323 (1.554–5.001)	0.014
Log NT-proBNP (1 SD increase)	2.030 (1.258–3.275)	0.004
Log CRP (1 SD increase)	1.518 (1.067–2.161)	0.020
Heart rate (1 b.p.m. increase)	1.033 (1.014–1.051)	0.001
Heart rate ≥ 75 b.p.m. (present)	1.858 (1.155–2.989)	0.011
HGS (1 kg increase)	0.955 (0.932–0.979)	< 0.001
Multivariable model^a		
Age (years)	0.954 (0.916–0.994)	0.025
Cachexia (present)	4.334 (1.767–10.631)	0.001
Dyspnoea (present)	3.725 (1.540–9.010)	0.004
(NYHA class ≥ II)		
HR (1 b.p.m. increase)	1.036 (1.004–1.068)	0.025
HGS (1 kg increase)	0.932 (0.878–0.990)	0.022

BMI, body mass index; CI, confidence interval; CRP, C-reactive protein; HGS, hand grip strength; HR, heart rate; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; QoL, quality of life; TSAT, transferrin saturation.

^aAdjusted for age, sex, solid tumour, treatment naïve, BMI, cachexia, dyspnoea (NYHA ≥ II), albumin, HR, HGS, and anaemia. The bold values indicate significant P-values (defined as $P \leq 0.05$).

Discussion

The aim of this study was to quantitate the influence of parameters deemed clinically relevant on QoL. We found that a number of clinical factors contribute to reduced QoL in our multivariate model, notably younger age, the presence of cachexia and dyspnoea, higher heart rate, and lower HGS, all of which remained independently associated with lower values in the EORTC QLQ-C30 even after adjusting for several confounders. Some factors may be targets for specific therapies that could be added to cancer treatment algorithms.

The EORTC QLQ-C30 has proven to be a valuable tool in the assessment of QoL in patients with cancer,^{6–8} in whom reduced QoL has been well established by several previous studies.^{9–11} Different studies have identified pain, fatigue, and limitations in social and physical functions as primary determinants of reduced QoL.^{12,13} Whilst oncological assessment tools are understandably focusing on cancer-specific complaints for assessing QoL, we sought to establish a cardiological perspective. This approach is reasonable not only because cancer and cardiovascular diseases are the two leading causes of death but also because there is gross overlap between the two disease groups in terms of their underlying mechanisms and risk factors.¹⁴ Therefore, it is not surprising that cancer patients develop cardiovascular perturbations independent of whether a cancer-specific therapy has been commenced or whether patients are still chemotherapy naïve.¹⁵

Like in patients with cancer, QoL is significantly reduced in patients with heart failure, a clinical syndrome that can manifest as a result of cardiotoxic chemotherapies. Because heart failure has 1 year mortality rates up to 17%, its prognosis is per se comparable with several types of cancer.¹⁶ The comparison between cancer and heart failure is advisable not only because of the interplay of both diseases but also because of the known impaired QoL.¹⁷ Improvements in QoL in patients with heart failure remain extremely challenging due to a lack of efficacy of most standard medications in this regard. Our group has investigated heart failure medications on their effectiveness at improving exercise capacity and QoL. However, the results with respect to QoL were disappointing with ivabradine, supplementation of intravenous iron, and exercise training being the only therapies to effectively improve QoL as well as exercise capacity.¹⁸ Interestingly, it was not possible to reveal a positive effect of heart rate reduction using beta-blockers. The fact that iron deficiency and elevated heart rate influence QoL in patients with heart failure is known, but now we were able to demonstrate this parallelism in cancer patients with regard to the interplay between increased heart rate and impaired QoL.^{19–21} Interestingly, in both conditions—cancer and heart failure—an increased heart rate is associated not only with reduced QoL but also with higher mortality.^{22–24} Therefore, it appears beneficial to initiate heart rate-modulating medications in patients with cancer as well. Unfortunately, evidence from clinical trials to support this view is not currently available outside the area of heart failure and cardiovascular disease.

Whereas heart rate is important for haemodynamic considerations, iron availability is essential for mobility due to its pivotal roles in skeletal muscle and myocardial respiration as well as in erythropoiesis. Muscle wasting can determine exercise capacity and thus mobility.^{25,26} In the absence of detailed body composition analyses, weight loss and therefore cachexia can serve as surrogate markers for the loss of muscle and fat mass. Cachexia is a common co-morbidity in heart failure and cancer patients. Its prevalence varies due

to inconsistent definitions and reaches 10–39% in heart failure patients.²⁷ Comparable prevalence data exist for patients with colorectal (22–55%) and lung cancer (46%), which is well in line with the prevalence of cachexia in the present study of 46.3%.^{28,29}

The relationship between cachexia and QoL as well as that between cachexia and increased mortality is described for patients with cancer and patients with heart failure.^{30–33} There are some explanatory approaches that show possible causes of an association between cachexia and reduced QoL: (i) Cachexia leads to a loss of muscle mass, which may result in a reduced physical capacity, fatigue, and dyspnoea.^{34,35} (ii) Cachexia leads to reduced cancer treatment efficacy and to an increase in treatment side effects.³⁶ Due to the multifactorial genesis, a multimodal therapeutic approach is required. This is reinforced by the fact that studies that only followed one therapeutic approach gave negative results. Cachexia therapy is based on combating the underlying tumour disease and is supplemented by measures to improve food tolerance, nutritional advice, and physical activity or training. The latter seems to be important not only to oppose cachexia but also to improve muscle strength. Although cancer-specific treatment is usually felt as a passive procedure, physical activity or exercise training can be influenced by the patient, resulting in improved self-esteem and consequently improved QoL.^{37–39} It is important to emphasize that physical activity and exercise training are usually not considered harmful at any point during cancer treatment.^{40,41} The meaning of muscle strength was also observed in our study, where a reduced HGS was associated with a lower QoL, which is in line with other studies.^{42–44} Marques *et al.* see a possible connection between reduced HGS and reduced QoL in the fact that the HGS represents the total muscle mass and a reduced muscle mass may lead to a loss of activity and autonomy.⁴⁵ On the other hand, reduced HGS may be interpreted just as a common pathway that reflects the overall condition of the individual. There is evidence that pain, for example, negatively affects muscle mass.⁴⁶ Pain itself notoriously affects QoL as mentioned before. Besides QoL, HGS was proven to be associated with different outcome parameters. In the field of surgery, reduced HGS was associated with an increased incidence of complications and longer hospital stays.⁴⁷ In cancer patients, it was also associated with an increased mortality.⁴⁸ Apart from the already mentioned, our results reveal that dyspnoea influences QoL in cancer patients directly. This is particularly important because data from the National Hospice Study have shown that 70.2% of terminally ill cancer patients report dyspnoea. Interestingly, 23.9% of these patients did not have any underlying cardiac or respiratory disease nor lung or pleural cancer involvement. Therefore, breathlessness has been attributed to the poor overall health status commonly encountered in advanced malignant disease.⁴⁹ Indeed, dyspnoea is associated with reduction in QoL as confirmed in

many studies and as is easily understandable for a feeling of intense tightening in the chest, air hunger, or breathlessness.^{50,51} Besides the use of oxygen and the prescription of morphine derivatives, it should be searched for treatable causes. For example, if there is heart failure as a result of tumour therapy, heart failure treatment can be initiated and diuretics can be administered to address signs of pulmonary venous congestion.

Interestingly, in our study, there were no differences in terms of survival between patients with reduced QoL and patients with higher QoL. Although this finding seems initially counterintuitive, it has to be taken into account that only 38% of cancer patients were dying from cancer itself, whereas the majority died due to other causes like cardiovascular diseases accordingly to Sturgeon *et al.*⁵² However, we cannot exclude that this finding in our cohort may be a chance finding.

In summary, increased heart rate, cachexia, and muscle strength represent important measures and therapeutic targets for improving QoL in patients with advanced cancer. Clinical trials are warranted to tackle these problems. Another interesting possibility embraces the treatment of iron deficiency, even though it was not associated with reduced QoL in the present study, likely due to the equal distribution of iron deficiency prevalence between patients with lower and higher QoL. Dyspnoea as a treatment target may be directly associated with muscle loss and reduced exercise capacity or with increased heart rate.

Limitations

Some limitations need to be addressed. First, the current study included all-comers of a regional cancer centre specialized in the treatment of gastroenterological and haematological cancers. The all-comer status resulted in a lot of patients who were on a second- or even third-line therapy. Therefore, most of the patients received cardiotoxic chemotherapy at the time of inclusion or in the past. However, our study aimed to assess determinants of QoL from a cardiologist perspective in cancer patients independently of the chemotherapy they received. Second, symptoms like pain, nausea, and vomiting were not included in the statistical analysis regarding determinants of QoL because they are already part of the EORTC QLQ-C30 questionnaire and their inclusion would result in selection bias. Third, we did not perform analyses of echocardiography parameters and QoL, because patients with relevant cardiovascular disease were excluded as per study design.

Conclusions

Our study shows that age, heart rate, HGS, and the presence of cachexia and dyspnoea are independent predictors of

reduced QoL. It is therefore desirable that these parameters are routinely screened for during oncological consultation to start interventions as early as possible in order to maintain patients' QoL as long as possible. Other parameters affecting QoL outside the present study such as pain, nausea, or vomiting should of course not be neglected. Further investigations are needed to evaluate the impact of heart rate-modulating medications in the setting of cancer.

Acknowledgements

Open Access funding enabled and organized by Projekt DEAL.

Conflict of interest

The authors declare no conflict of interest with respect to this work.

Funding

This research received no external funding.

References

- Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, Kaasa S, Klee M, Osoba D, Razavi D, Rofe PB, Schraub S, Sneeuw K, Sullivan M, Takeda F. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. *J Natl Cancer Inst.* 1993; **85**: 365–376.
- Sprangers MA, Cull A, Groenvold M, Bjordal K, Blazeby J, Aaronson NK. The European Organization for Research and Treatment of cancer approach to developing questionnaire modules: an update and overview. EORTC Quality of Life Study Group. *Qual Life Res.* 1998; **7**: 291–300.
- Williams B, Mancia G, Spiering W, Rosei EA, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I. 2018 ESC/ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). *G Ital Cardiol (Rome).* 2018; **19**: 3S–73S.
- Fayers PMANK, Bjordal K, Groenvold M, Curran D, Bottomley A. EORTC QLQ-C30 Scoring Manual. 2001.
- Giesinger JM, Kuijpers W, Young T, Tomaszewski KA, Friend E, Zabernigg A, Holzner B, Aaronson NK. Thresholds for clinical importance for four key domains of the EORTC QLQ-C30: physical functioning, emotional functioning, fatigue and pain. *Health Qual Life Outcomes.* 2016; **14**: 87.
- Bottomley A, Therasse P, Piccart M, Efficace F, Coens C, Gotay C, Welnicka-Jaskiewicz M, Mauriac L, Dyczka J, Cufer T, Lichinitser MR, Schornagel JH, Bonnefoi H, Shepherd L, European Organisation for Research and Treatment of Cancer Breast Cancer Group, National Cancer Institute of Canada, Swiss Group for Clinical Cancer Research. Health-related quality of life in survivors of locally advanced breast cancer: an international randomised controlled phase III trial. *Lancet Oncol.* 2005; **6**: 287–294.
- Andre T, Amonkar M, Norquist JM, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt CJA, Smith D, Garcia-Carbonero R, Sevilla I, de la Fouchardiere C, Rivera F, Elez E, Diaz LA Jr, Yoshino T, van Cutsem E, Yang P, Farooqui M, le DT. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial. *Lancet Oncol.* 2021; **22**: 665–677.
- Wick W, Gorlia T, Bendszus M, Taphoorn M, Sahn F, Harting I, Brandes AA, Taal W, Domont J, Idhah A, Campone M, Clement PM, Stupp R, Fabbro M, le Rhun E, Dubois F, Weller M, von Deimling A, Golfinopoulos V, Bromberg JC, Platten M, Klein M, van den Bent MJ. Lomustine and bevacizumab in progressive glioblastoma. *N Engl J Med.* 2017; **377**: 1954–1963.
- Arndt V, Merx H, Stegmaier C, Ziegler H, Brenner H. Quality of life in patients with colorectal cancer 1 year after diagnosis compared with the general population: a population-based study. *J Clin Oncol.* 2004; **22**: 4829–4836.
- Jansen L, Koch L, Brenner H, Arndt V. Quality of life among long-term (≥5 years) colorectal cancer survivors—systematic review. *Eur J Cancer.* 2010; **46**: 2879–2888.
- Annunziata MA, Muzzatti B, Flaiban C, Gipponi K, Carnaghi C, Tralongo P, Caruso M, Cavina R, Tirelli U. Long-term quality of life profile in oncology: a comparison between cancer survivors and the general population. *Support Care Cancer.* 2018; **26**: 651–656.
- Rustoen T, Moum T, Padilla G, Paul S, Miaskowski C. Predictors of quality of life in oncology outpatients with pain from bone metastasis. *J Pain Symptom Manage.* 2005; **30**: 234–242.
- Beijer S, Kempen GI, Pijls-Johannesma MC, de Graeff A, Dagnelie PC. Determinants of overall quality of life in preterminal cancer patients. *Int J Cancer.* 2008; **123**: 232–235.
- Koene RJ, Prizment AE, Blaes A, Konety SH. Shared risk factors in cardiovascular disease and cancer. *Circulation.* 2016; **133**: 1104–1114.
- Cramer L, Hildebrandt B, Kung T, Wichmann K, Springer J, Doehner W, Sandek A, Valentova M, Stojakovic T, Scharnagl H, Riess H, Anker SD, von Haehling S. Cardiovascular function and predictors of exercise capacity in patients with colorectal cancer. *J Am Coll Cardiol.* 2014; **64**: 1310–1319.
- Mamas MA, Sperrin M, Watson MC, Coutts A, Wilde K, Burton C, Kadam UT, Kwok CS, Clark AB, Murchie P, Buchan I, Hannaford PC, Myint PK. Do patients have worse outcomes in heart failure than in cancer? A primary care-based cohort study with 10-year follow-up in Scotland. *Eur J Heart Fail.* 2017; **19**: 1095–1104.
- Heo S, Lennie TA, Okoli C, Moser DK. Quality of life in patients with heart failure: ask the patients. *Heart Lung.* 2009; **38**: 100–108.
- von Haehling S, Arzt M, Doehner W, Edelmann F, Evertz R, Ebner N, Herrmann-Lingen C, Garfias Macedo T, Koziolok M, Noutsias M, Schulze PC, Wachter R, Hasenfuß G, Laufs U. Improving exercise capacity and quality of life using non-invasive heart failure treatments: evidence from clinical trials. *Eur J Heart Fail.* 2021; **23**: 92–113.
- Zusman O, Itzhaki Ben Zadok O, Gafer-Gvili A. Management of iron deficiency in heart failure. *Acta Haematol.* 2019; **142**: 51–56.

20. Alcaide-Aldeano A, Garay A, Alcobero L, Jiménez-Marrero S, Yun S, Tajés M, García-Romero E, Díez-López C, González-Costello J, Mateus-Porta G, Cainzos-Achirica M, Enjuanes C, Comín-Colet J, Moliner P. Iron deficiency: impact on functional capacity and quality of life in heart failure with preserved ejection fraction. *J Clin Med*. 2020; **9**.
21. Ekman I, Chassany O, Komajda M, Bohm M, Borer JS, Ford I, Tavazzi L, Swedberg K. Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study. *Eur Heart J*. 2011; **32**: 2395–2404.
22. Anker MS, Frey MK, Goliasch G, Bartko PE, Prausmüller S, Gisslinger H, Kornek G, Strunk G, Raderer M, Zielinski C, Hülsmann M, Pavo N. Increased resting heart rate and prognosis in treatment-naive unselected cancer patients: results from a prospective observational study. *Eur J Heart Fail*. 2020; **22**: 1230–1238.
23. Lau K, Malik A, Foroutan F, Buchan TA, Daza JF, Sekercioglu N, Orchanian-Cheff A, Alba AC. Resting heart rate as an important predictor of mortality and morbidity in ambulatory patients with heart failure: a systematic review and meta-analysis. *J Card Fail*. 2021; **27**: 349–363.
24. Lee DH, Park S, Lim SM, Lee MK, Giovannucci EL, Kim JH, Kim SI, Jeon JY. Resting heart rate as a prognostic factor for mortality in patients with breast cancer. *Breast Cancer Res Treat*. 2016; **159**: 375–384.
25. Fulster S, Tacke M, Sandek A, Ebner N, Tschöpe C, Doehner W, Anker SD, von Haehling S. Muscle wasting in patients with chronic heart failure: results from the studies investigating co-morbidities aggravating heart failure (SICA-HF). *Eur Heart J*. 2013; **34**: 512–519.
26. von Haehling S, Garfias Macedo T, Valentova M, Anker MS, Ebner N, Bekfani T, Haarmann H, Schefold JC, Lainscak M, Cleland JGF, Doehner W, Hasenfuss G, Anker SD. Muscle wasting as an independent predictor of survival in patients with chronic heart failure. *J Cachexia Sarcopenia Muscle*. 2020; **11**: 1242–1249.
27. Valentova M, Anker SD, von Haehling S. Cardiac cachexia revisited: the role of wasting in heart failure. *Heart Fail Clin*. 2020; **16**: 61–69.
28. Thoresen L, Frykholm G, Lydersen S, Ulveland H, Baracos V, Prado CM, Birdsall L, Falkmer U. Nutritional status, cachexia and survival in patients with advanced colorectal carcinoma. Different assessment criteria for nutritional status provide unequal results. *Clin Nutr*. 2013; **32**: 65–72.
29. Zhu R, Liu Z, Jiao R, Zhang C, Yu Q, Han S, Duan Z. Updates on the pathogenesis of advanced lung cancer-induced cachexia. *Thorax Cancer*. 2019; **10**: 8–16.
30. Wallengren O, Lundholm K, Bosaeus I. Diagnostic criteria of cancer cachexia: relation to quality of life, exercise capacity and survival in unselected palliative care patients. *Support Care Cancer*. 2013; **21**: 1569–1577.
31. Fearon KC, Voss AC, Hustead DS, Cancer Cachexia Study Group. Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. *Am J Clin Nutr*. 2006; **83**: 1345–1350.
32. Bland KA, Harrison M, Zopf EM, Sousa MS, Currow DC, Ely M, Agar M, Butcher BE, Vaughan V, Dowd A, Martin P. Quality of life and symptom burden improve in patients attending a multidisciplinary clinical service for cancer cachexia: a retrospective observational review. *J Pain Symptom Manage*. 2021; **62**: e164–e176.
33. Anker SD, Coats AJ. Cardiac cachexia: a syndrome with impaired survival and immune and neuroendocrine activation. *Chest*. 1999; **115**: 836–847.
34. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, Davis M, Muscaritoli M, Ottery F, Radbruch L, Ravasco P, Walsh D, Wilcock A, Kaasa S, Baracos VE. Definition and classification of cancer cachexia: an international consensus. *Lancet Oncol*. 2011; **12**: 489–495.
35. Grande AJ, Silva V, Maddocks M. Exercise for cancer cachexia in adults: executive summary of a Cochrane Collaboration systematic review. *J Cachexia Sarcopenia Muscle*. 2015; **6**: 208–211.
36. Bozzetti F. Nutritional support of the oncology patient. *Crit Rev Oncol Hematol*. 2013; **87**: 172–200.
37. Imran M, Al-Wassia R, Alkhayyat SS, Baig M, Al-Saati BA. Assessment of quality of life (QoL) in breast cancer patients by using EORTC QLQ-C30 and BR-23 questionnaires: a tertiary care center survey in the western region of Saudi Arabia. *PLoS ONE*. 2019; **14**: e0219093.
38. Courneya KS, Mackey JR, Bell GJ, Jones LW, Field CJ, Fairey AS. Randomized controlled trial of exercise training in postmenopausal breast cancer survivors: cardiopulmonary and quality of life outcomes. *J Clin Oncol*. 2003; **21**: 1660–1668.
39. Klassen O, Konig A, von Haehling S, Bräulke F. Cardiovascular fitness in oncology: exercise and sport. *Internist (Berl)*. 2020; **61**: 1140–1150.
40. Heywood R, McCarthy AL, Skinner TL. Safety and feasibility of exercise interventions in patients with advanced cancer: a systematic review. *Support Care Cancer*. 2017; **25**: 3031–3050.
41. Brown JC, Winters-Stone K, Lee A, Schmitz KH. Cancer, physical activity, and exercise. *Compr Physiol*. 2012; **2**: 2775–2809.
42. Jakobsen LH, Rask IK, Kondrup J. Validation of handgrip strength and endurance as a measure of physical function and quality of life in healthy subjects and patients. *Nutrition*. 2010; **26**: 542–550.
43. Kim H, Yoo S, Kim H, Park SG, Son M. Cancer survivors with low hand grip strength have decreased quality of life compared with healthy controls: the Korea National Health and Nutrition Examination Survey 2014–2017. *Korean J Fam Med*. 2021; **42**: 204–211.
44. Paek J, Choi YJ. Association between hand grip strength and impaired health-related quality of life in Korean cancer survivors: a cross-sectional study. *BMJ Open*. 2019; **9**: e030938.
45. Marques LP, Confortin SC, Ono LM, Barbosa AR, d'Orsi E. Quality of life associated with handgrip strength and sarcopenia: EpiFloripa Aging Study. *Arch Gerontol Geriatr*. 2019; **81**: 234–239.
46. Henriksen M, Rosager S, Aaboe J, Graven-Nielsen T, Bliddal H. Experimental knee pain reduces muscle strength. *J Pain*. 2011; **12**: 460–467.
47. Bohannon RW. Dynamometer measurements of hand-grip strength predict multiple outcomes. *Percept Mot Skills*. 2001; **93**: 323–328.
48. Kalfarentzos F, Spiliotis J, Velimezis G, Dougenis D, Androulakis J. Comparison of forearm muscle dynamometry with nutritional prognostic index, as a preoperative indicator in cancer patients. *JPEN J Parenter Enteral Nutr*. 1989; **13**: 34–36.
49. Reuben DB, Mor V. Dyspnea in terminally ill cancer patients. *Chest*. 1986; **89**: 234–236.
50. Damani A, Ghoshal A, Salins N, Deodhar J, Muckaden M. Prevalence and intensity of dyspnea in advanced cancer and its impact on quality of life. *Indian J Palliat Care*. 2018; **24**: 44–50.
51. Roberts DK, Thorne SE, Pearson C. The experience of dyspnea in late-stage cancer. Patients' and nurses' perspectives. *Cancer Nurs*. 1993; **16**: 310–320.
52. Sturgeon KM, Deng L, Bluethmann SM, Zhou S, Trifiletti DM, Jiang C, Kelly SP, Zaorsky NG. A population-based study of cardiovascular disease mortality risk in US cancer patients. *Eur Heart J*. 2019; **40**: 3889–3897.